Skip to main content
Premium Trial:

Request an Annual Quote

HBIO to Divest Capital Equipment Business; Postpones Q2 Earnings Report

NEW YORK, July 28 (GenomeWeb News) - Harvard Bioscience plans to divest its capital equipment business, which includes the Genomic Solutions product line, the company said yesterday.

 

HBIO also said it has postponed its second-quarter earnings report, originally scheduled for today, until Aug. 8. This will allow the company to complete a review of whether the capital equipment business segment met the criteria for "held for sale" accounting treatment as of June 30 under GAAP financial statement rules.

 

HBIO said that second-quarter results for the capital equipment business, which includes the COPAS and Genomic Solution product lines, "fell short of the company's expectations." As a result, HBIO expects to record "significant impairment charges related to goodwill and other intangible assets" as well as "significant charges related to the previously announced restructuring activities."

 

The way in which these charges will be presented in the second-quarter earnings will depend on the outcome of the review, according to the company.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.